| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.06M | 2.06M | 2.14M | 1.50M | 973.00K | 467.66K |
| Gross Profit | 2.06M | 2.06M | 2.14M | -53.74K | 922.59K | 435.36K |
| EBITDA | -6.94M | -6.94M | -5.11M | -8.66M | -14.97M | -3.24M |
| Net Income | -6.97M | -6.97M | -4.80M | -9.05M | -14.12M | -7.84M |
Balance Sheet | ||||||
| Total Assets | 17.47M | 17.47M | 22.89M | 27.21M | 30.17M | 19.69M |
| Cash, Cash Equivalents and Short-Term Investments | 13.82M | 13.82M | 18.78M | 24.19M | 28.17M | 8.93M |
| Total Debt | 14.97K | 14.97K | 109.31K | 9.10K | 19.75K | 30.09K |
| Total Liabilities | 752.16K | 752.16K | 1.09M | 1.21M | 746.23K | 732.71K |
| Stockholders Equity | 16.72M | 16.72M | 21.80M | 26.00M | 29.42M | 18.96M |
Cash Flow | ||||||
| Free Cash Flow | -4.19M | -4.19M | -4.99M | -3.21M | -4.44M | -2.32M |
| Operating Cash Flow | -4.19M | -4.19M | -4.79M | -3.03M | -4.30M | -2.22M |
| Investing Cash Flow | 4.11M | 4.11M | 6.98M | 2.31M | -94.83K | -262.25K |
| Financing Cash Flow | -96.30K | -96.30K | -115.82K | 64.90K | 24.62M | 606.22K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$59.60M | 4.37 | 13.76% | 6.06% | -18.05% | -51.45% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
50 Neutral | AU$22.67M | -2.12 | -112.59% | ― | ― | -67.74% | |
49 Neutral | AU$91.74M | -12.96 | -35.59% | ― | ― | -45.74% | |
49 Neutral | AU$874.25M | -21.11 | -50.48% | ― | 333.23% | 10.83% | |
38 Underperform | AU$356.97M | -9.41 | -149.70% | ― | 503.29% | 11.46% | |
33 Underperform | AU$92.48M | -31.25 | ― | ― | 44.80% | 7.69% |
Archer Materials Limited announced that Kenneth Graham Williams has ceased to be a director as of December 1, 2025. Williams held 3,000,000 unlisted options through the KG & PC Williams Family Trust, which are exercisable at $0.5344 each and expire on June 30, 2028. This change in directorship may impact the company’s governance and strategic direction.
Archer Materials Limited has announced the appointment of Andrew Ian Just as a new director, effective from December 1, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team, although the new director currently holds no securities or interests in the company. This move is expected to enhance Archer Materials’ governance and potentially influence its strategic direction and stakeholder relations.
Archer Materials Limited has announced changes to its board with the appointment of Andrew Just as a Non-Executive Director and the retirement of Ken Williams. Andrew Just brings extensive experience in the medical device and healthcare industries, which aligns with Archer’s strategic growth in medical diagnostics technologies. The board expressed gratitude to Ken Williams for his significant contributions over the past five years, including overseeing the company’s transition from mineral exploration to a quantum and medical device company.
Archer Materials Limited has announced a change in the director’s interest, specifically involving Gregory David English. The change includes the issuance of 660,867 Performance Rights following shareholder approval at the company’s Annual General Meeting. This adjustment in director’s interest reflects the company’s ongoing governance practices and may influence stakeholder perceptions regarding leadership alignment with company goals.
Archer Materials Limited has announced the presentation to be delivered by its CEO, Dr. Simon Ruffell, at the company’s Annual General Meeting. This announcement underscores Archer’s ongoing commitment to innovation in the semiconductor sector, particularly in quantum computing and medical diagnostics, which could significantly impact its market positioning and stakeholder interests.
Archer Materials has partnered with CSIRO, Australia’s National Science Agency, to develop Quantum Machine Learning (QML) models aimed at enhancing fraud detection in financial transactions. This collaboration, running from November 2025 to November 2026, seeks to leverage CSIRO’s expertise to create innovative QML models that offer improved reliability and speed in identifying fraudulent activities. The project underscores Archer’s strategy to commercialize near-term quantum applications with global impact, potentially extending QML’s applications beyond finance to sectors like healthcare, energy, and cybersecurity.
Archer Materials Limited announced the cessation of 123,879 performance rights due to unmet conditions, impacting its issued capital structure. This development may influence the company’s strategic planning and stakeholder perceptions, as performance rights are often linked to employee incentives and company growth targets.
Archer Materials has announced successful initial results from its collaboration with IMEC on the development of a silicon-based Biochip for blood potassium sensing. The silicon devices achieved a potassium sensing accuracy of ±0.3 mM, matching clinical standards and offering faster readout times compared to current technologies. This advancement de-risks the Biochip supply chain, reduces costs, and accelerates commercialization. Archer plans to further refine the technology and pursue regulatory approvals, aiming for clinical trials and productization focused on chronic kidney disease diagnostics.
Archer Materials has made significant progress in its core areas of focus during the first quarter of FY26. The company advanced its 12CQ project by enhancing the readout of quantum information, bringing it closer to qubit functionality. Additionally, improvements in potassium ion testing on its biochip platform have brought it closer to clinical readiness, with a partnership with IMEC further accelerating development. Archer also demonstrated the operation of TMR sensors at cryogenic temperatures, which could have applications in quantum computing and aerospace. The company maintains a strong cash position with $11.6 million and no debt, supporting its R&D and commercial activities.
Archer Materials Limited announced that its CEO, Dr. Simon Ruffell, will present at the Semiconductor Australia 2025 conference. This presentation highlights Archer’s ongoing efforts to position itself as a leader in semiconductor innovation, potentially impacting its market presence and stakeholder interests.
Archer Materials Limited has announced its Annual General Meeting (AGM) for 2025, scheduled to take place on November 20th at the Stone & Chalk Sydney Scaleup Hub. The company encourages shareholders to participate either in person or by proxy, emphasizing the importance of shareholder engagement in the decision-making process. This meeting is a significant event for Archer Materials as it provides an opportunity for stakeholders to discuss the company’s strategic direction and operational updates.
Archer Materials has entered into a collaboration with Emergence Quantum to accelerate the development of quantum technology. This partnership focuses on utilizing graphene and carbon-based materials to advance next-generation quantum and electronic devices. The collaboration is structured around a phased Innovation and Commercialisation Program, which aims to translate scientific discoveries into practical technologies, thereby strengthening Archer’s position as a leader in quantum materials and device technology. Emergence Quantum’s expertise in strategic quantum technology development will support Archer in creating commercially viable products, enhancing its industry positioning and potential impact on stakeholders.
Archer Materials has achieved significant progress in its carbon-based qubit technology, building on its earlier EDMR breakthrough. The company has successfully demonstrated reproducible device performance and wafer-scale synthesis of its proprietary carbon material, which is compatible with CMOS technology. These advancements position Archer at the forefront of quantum computing innovation, with plans for a targeted qubit demonstration in mid-2026. The developments enhance Archer’s ability to produce scalable quantum devices that operate at room temperature, potentially impacting the quantum computing and sensing industries.
Archer Materials Limited has announced that its 2025 Annual General Meeting (AGM) will be held on November 20, 2025. A key agenda item will be the re-election of directors, with the deadline for director nominations set for October 2, 2025. This meeting is significant for stakeholders as it involves leadership decisions that could impact the company’s strategic direction and industry positioning.
Archer Materials Limited has released an updated investor presentation, highlighting its ongoing efforts in the semiconductor industry. This development underscores Archer’s commitment to advancing semiconductor technologies, which could significantly impact its market position and offer potential benefits to stakeholders through its innovative quantum computing and medical diagnostic chips.
Archer Materials Limited has announced the issuance of 1,474,962 performance rights as part of an employee incentive scheme, which are not intended to be quoted on the ASX. This move is likely aimed at motivating and retaining key personnel, potentially impacting the company’s operational efficiency and positioning within the advanced materials industry.